{"id":5788,"date":"2026-07-31T13:33:00","date_gmt":"2026-07-31T13:33:00","guid":{"rendered":"https:\/\/ventil.rs\/blog\/health\/novo-nordisk-shares-dive-after-heart-medicine-fails-trial-dealing-another-blow-to-its-pipeline\/"},"modified":"2026-07-31T13:33:00","modified_gmt":"2026-07-31T13:33:00","slug":"novo-nordisk-shares-dive-after-heart-medicine-fails-trial-dealing-another-blow-to-its-pipeline","status":"publish","type":"post","link":"https:\/\/ventil.rs\/blog\/health\/novo-nordisk-shares-dive-after-heart-medicine-fails-trial-dealing-another-blow-to-its-pipeline\/","title":{"rendered":"Novo Nordisk shares dive after heart medicine fails trial, dealing another blow to its  pipeline"},"content":{"rendered":"<p> <br \/>\n<\/p>\n<div id=\"RegularArticle-ArticleBody-5\" data-module=\"ArticleBody\" data-test=\"articleBody-2\" data-analytics=\"RegularArticle-articleBody-5-2\"><span class=\"HighlightShare-hidden\" style=\"top:0;left:0\"\/><\/p>\n<div class=\"group\">\n<p>Shares of <span class=\"QuoteInBody-quoteNameContainer\" data-test=\"QuoteInBody\" id=\"RegularArticle-QuoteInBody-1\"><a href=\"https:\/\/www.cnbc.com\/quotes\/NVO\/\">Novo Nordisk<\/a><span class=\"QuoteInBody-inlineButton\"><span class=\"AddToWatchlistButton-watchlistContainer\" id=\"-WatchlistDropdown\" data-analytics-id=\"-WatchlistDropdown\"><button class=\"AddToWatchlistButton-watchlistButton\" aria-label=\"Add To Watchlist\" data-testid=\"dropdown-btn\"><span class=\"AddToWatchlistButton-addWatchListFromTag\"\/><\/button><\/span><\/span><\/span> fell as much as 10% on Friday after the drugmaker said a late-stage heart drug trial failed to reduce major adverse cardiovascular events, or MACE, compared to a placebo.<\/p>\n<p>While the experimental medicine, ziltivekimab, did show some biological effect, it didn&#8217;t translate into a statistically meaningful reduction in MACE, defined as cardiovascular death, non-fatal heart attack or non-fatal stroke, for patients with certain diseases, <a href=\"https:\/\/www.novonordisk.com\/content\/nncorp\/global\/en\/news-and-media\/news-and-ir-materials\/news-details.html?id=916587\" target=\"_blank\">Novo said in a statement<\/a> on Friday.<\/p>\n<p>The missed endpoint is the latest blow to the Danish drugmaker, which is racing to restore investor confidence in its pipeline and ability to execute, especially in the challenging U.S. market.<\/p>\n<p>&#8220;While ziltivekimab did not achieve the MACE benefit we had hoped for, this does not change our strategic commitment to cardiovascular disease,&#8221; chief scientific officer Martin Holst Lange said.<\/p>\n<p>Copenhagen-listed shares were last seen down 7.4% while its American depositary receipts were 8.6% lower in premarket trading, on track for their worst day since February when the company released <a href=\"https:\/\/www.cnbc.com\/2026\/02\/23\/novo-nordisk-stock-cagrisema-trial-fails-weight-loss.html\">disappointing results from a head-to-head trial<\/a> of its <a href=\"https:\/\/www.cnbc.com\/2026\/07\/29\/novo-nordisk-lawsuit-cagrisema-weight-loss-drug.html\">next-generation weight-loss drug CagriSema<\/a> versus Eli Lilly&#8217;s rival medicine. If losses hold, shares will turn negative for the year.<\/p>\n<p>Jefferies and Citi analysts both said the share move seemed disproportionate given ziltivekimab&#8217;s small contribution to Novo&#8217;s overall portfolio.<\/p>\n<p>However, &#8220;the result is strategically negative as it removes one of Novo&#8217;s more credible non-obesity growth opportunities and again reinforces the company&#8217;s reliance on commercial execution in obesity and sourcing external innovation for driving growth,&#8221; Jefferies said.<\/p>\n<\/div>\n<div>\n<div class=\"Collapsible-proliveCollapsableContainer\" role=\"button\" tabindex=\"0\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"256\" height=\"256\" viewbox=\"0 0 256 256\" aria-labelledby=\"title desc\" role=\"img\" focusable=\"false\" preserveaspectratio=\"xMinYMin\" class=\"Collapsible-stockChartIcon\"><title>Stock Chart Icon<\/title><desc>Stock chart icon<\/desc><g transform=\"translate(1.4065934065934016 1.4065934065934016) scale(2.81 2.81)\"><path d=\"M 87.994 0 H 69.342 c -1.787 0 -2.682 2.16 -1.418 3.424 l 5.795 5.795 l -33.82 33.82 L 28.056 31.196 l -3.174 -3.174 c -1.074 -1.074 -2.815 -1.074 -3.889 0 L 0.805 48.209 c -1.074 1.074 -1.074 2.815 0 3.889 l 3.174 3.174 c 1.074 1.074 2.815 1.074 3.889 0 l 15.069 -15.069 l 14.994 14.994 c 1.074 1.074 2.815 1.074 3.889 0 l 1.614 -1.614 c 0.083 -0.066 0.17 -0.125 0.247 -0.202 l 37.1 -37.1 l 5.795 5.795 C 87.84 23.34 90 22.445 90 20.658 V 2.006 C 90 0.898 89.102 0 87.994 0 z\" transform=\" matrix(1 0 0 1 0 0) \" stroke-linecap=\"round\"\/><path d=\"M 65.626 37.8 v 49.45 c 0 1.519 1.231 2.75 2.75 2.75 h 8.782 c 1.519 0 2.75 -1.231 2.75 -2.75 V 23.518 L 65.626 37.8 z\" transform=\" matrix(1 0 0 1 0 0) \" stroke-linecap=\"round\"\/><path d=\"M 47.115 56.312 V 87.25 c 0 1.519 1.231 2.75 2.75 2.75 h 8.782 c 1.519 0 2.75 -1.231 2.75 -2.75 V 42.03 L 47.115 56.312 z\" transform=\" matrix(1 0 0 1 0 0) \" stroke-linecap=\"round\"\/><path d=\"M 39.876 60.503 c -1.937 0 -3.757 -0.754 -5.127 -2.124 l -6.146 -6.145 V 87.25 c 0 1.519 1.231 2.75 2.75 2.75 h 8.782 c 1.519 0 2.75 -1.231 2.75 -2.75 V 59.844 C 41.952 60.271 40.933 60.503 39.876 60.503 z\" transform=\" matrix(1 0 0 1 0 0) \" stroke-linecap=\"round\"\/><path d=\"M 22.937 46.567 L 11.051 58.453 c -0.298 0.298 -0.621 0.562 -0.959 0.8 V 87.25 c 0 1.519 1.231 2.75 2.75 2.75 h 8.782 c 1.519 0 2.75 -1.231 2.75 -2.75 V 48.004 L 22.937 46.567 z\" transform=\" matrix(1 0 0 1 0 0) \" stroke-linecap=\"round\"\/><\/g><\/svg><\/p>\n<div class=\"Collapsible-proLivePlayerCloseOrExpand\"><\/div>\n<\/div>\n<p><iframe title=\"Novo Nordisk ADRs year-to-date.\" src=\"https:\/\/www.cnbc.com\/appchart?symbol=NVO&amp;range=YTD&amp;type=mountain&amp;embedded=true&amp;$DEVICE$=undefined\" height=\"460\" scrolling=\"no\" loading=\"lazy\" style=\"border:0;width:100%\"><\/iframe><\/p>\n<p>Novo Nordisk ADRs year-to-date.<\/p>\n<\/div>\n<div class=\"group\">\n<p>The study tested whether ziltivekimab, which blocks the inflammatory IL-6 pathway, could reduce the risk of a first major cardiovascular event compared with placebo when added to standard treatment.<\/p>\n<p>The trial involved more than 6,300 people who had atherosclerotic cardiovascular disease, chronic kidney disease and elevated inflammation. <\/p>\n<p>Overall adverse-event rates were similar, although serious infections were more common with ziltivekimab. There was no difference in overall mortality.<\/p>\n<\/div>\n<h2 class=\"ArticleBody-subtitle\"><a id=\"headline0\"\/>Cautious optimism<\/h2>\n<div class=\"group\">\n<p>Friday&#8217;s blow came amid cautious investor optimism around Novo, mainly due to its successful launch of the Wegovy pill, the first oral GLP-1 for weight loss, in the U.S. in January.<\/p>\n<p>Eli Lilly launched a rival pill, Foundayo, in April, <a href=\"https:\/\/www.cnbc.com\/2026\/05\/04\/novo-nordisk-wegovy-pill-beating-eli-lilly-foundayo-early.html\">which has seen slower uptake.<\/a> <\/p>\n<p>Over the summer, Novo launched the pill in the UAE and the U.K., as it looks to translate the U.S. success globally.<\/p>\n<\/div>\n<div class=\"group\">\n<p>Novo shares are still far off where they were two years ago.<\/p>\n<p>Coming into Friday trading, the company&#8217;s Danish shares had fallen 7% year-to-date and were down about 70% from their mid-2024 peak. The company is facing intense pressure from\u00a0<span class=\"QuoteInBody-quoteNameContainer\" data-test=\"QuoteInBody\" id=\"RegularArticle-QuoteInBody-6\"><a href=\"https:\/\/www.cnbc.com\/quotes\/LLY\/\">Eli Lilly&#8217;s<\/a><span class=\"QuoteInBody-inlineButton\"><span class=\"AddToWatchlistButton-watchlistContainer\" id=\"-WatchlistDropdown\" data-analytics-id=\"-WatchlistDropdown\"><button class=\"AddToWatchlistButton-watchlistButton\" aria-label=\"Add To Watchlist\" data-testid=\"dropdown-btn\"><span class=\"AddToWatchlistButton-addWatchListFromTag\"\/><\/button><\/span><\/span><\/span>\u00a0rival medicines, which have rapidly\u00a0<a href=\"https:\/\/www.cnbc.com\/2026\/05\/18\/novo-nordisk-wegovy-pill-launch-eli-lilly-foundayo-weight-loss.html\">gained market share<\/a>.<\/p>\n<p>Even with the pill momentum, which both Novo and Lilly say is expanding the GLP-1 market rather than eating into the injectables market, Novo remains under pressure as prices are lower and the pill still only accounts for a fraction of its total sales. <\/p>\n<\/div>\n<div role=\"region\" aria-labelledby=\"Placeholder-ArticleBody-Video-108318901\">\n<div role=\"button\" tabindex=\"0\" id=\"Placeholder-ArticleBody-Video-108318901\" class=\"PlaceHolder-wrapper\" data-vilynx-id=\"7000415421\" data-test=\"VideoPlaceHolder\">\n<div class=\"InlineVideo-videoEmbed\" id=\"InlineVideo-0\" data-test=\"InlineVideo\">\n<div class=\"InlineVideo-wrapper\">\n<div class=\"InlineVideo-inlineThumbnailContainer\"><img decoding=\"async\" class=\"InlineVideo-videoThumbnail\" src=\"https:\/\/image.cnbcfm.com\/api\/v1\/image\/108318902-3ED1-REQ-060926-Novo-Clip1.jpg?v=1781021148&amp;w=750&amp;h=422&amp;vtcrop=y\" alt=\"Novo Nordisk CEO: '80% of Wegovy pill customers' have never taken a GLP-1 before\"\/><span class=\"InlineVideo-videoButton\"\/><span\/><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"group\">\n<p>Heightened competition has made Novo&#8217;s pipeline increasingly important to investors. The company is counting on products including\u00a0<a href=\"https:\/\/www.cnbc.com\/2026\/05\/12\/healthy-returns-novo-nordisk-releases-new-high-dose-wegovy-data.html\">higher-dose Wegovy<\/a>, oral versions of its medicines and CagriSema to help strengthen its market position.<\/p>\n<p>It&#8217;s set to report second-quarter earnings next week, which will provide the next insight for investors on how the obesity market is shaping up.<\/p>\n<\/div>\n<div class=\"ArticleBody-googlePreferredSourceContainer\" data-module=\"GooglePreferredSource\" data-id=\"RegularArticle-GooglePreferredSource-5\"><a href=\"https:\/\/www.google.com\/preferences\/source?q=https:\/\/www.cnbc.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.<\/a><\/div>\n<\/div>\n<p><br \/>\n<br \/><a href=\"https:\/\/www.cnbc.com\/2026\/07\/31\/novo-nordisk-trial-results.html\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shares of Novo Nordisk fell as much as 10% on Friday after the drugmaker said a late-stage heart drug trial failed to reduce major adverse cardiovascular events, or MACE, compared to a placebo. While the experimental medicine, ziltivekimab, did show some biological effect, it didn&#8217;t translate into a statistically meaningful reduction in MACE, defined as&#8230;<\/p>\n<p class=\"more-link-wrap\"><a href=\"https:\/\/ventil.rs\/blog\/health\/novo-nordisk-shares-dive-after-heart-medicine-fails-trial-dealing-another-blow-to-its-pipeline\/\" class=\"more-link\">Read More<span class=\"screen-reader-text\"> &ldquo;Novo Nordisk shares dive after heart medicine fails trial, dealing another blow to its  pipeline&rdquo;<\/span> &raquo;<\/a><\/p>\n","protected":false},"author":1,"featured_media":5789,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/image.cnbcfm.com\/api\/v1\/image\/108317499-1780677508664-gettyimages-2279271814-US_STOCKS.jpeg?v=1780677967&w=1920&h=1080","fifu_image_alt":"","footnotes":""},"categories":[4],"tags":[73,75,927,69,77,488,70,1711,259,156,426],"class_list":["post-5788","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-biotech-and-pharmaceuticals","tag-breaking-news-business","tag-breaking-news-markets","tag-business","tag-business-news","tag-eli-lilly-and-co","tag-health-care-industry","tag-medication","tag-novo-nordisk-a-s","tag-pharmaceuticals","tag-united-states"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v17.8 (Yoast SEO v22.1) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Novo Nordisk shares dive after heart medicine fails trial, dealing another blow to its pipeline - Breaking News<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ventil.rs\/blog\/health\/novo-nordisk-shares-dive-after-heart-medicine-fails-trial-dealing-another-blow-to-its-pipeline\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk shares dive after heart medicine fails trial, dealing another blow to its pipeline\" \/>\n<meta property=\"og:description\" content=\"Shares of Novo Nordisk fell as much as 10% on Friday after the drugmaker said a late-stage heart drug trial failed to reduce major adverse cardiovascular events, or MACE, compared to a placebo. While the experimental medicine, ziltivekimab, did show some biological effect, it didn&#8217;t translate into a statistically meaningful reduction in MACE, defined as...Read More &ldquo;Novo Nordisk shares dive after heart medicine fails trial, dealing another blow to its pipeline&rdquo; &raquo;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ventil.rs\/blog\/health\/novo-nordisk-shares-dive-after-heart-medicine-fails-trial-dealing-another-blow-to-its-pipeline\/\" \/>\n<meta property=\"og:site_name\" content=\"Breaking News\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-31T13:33:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/image.cnbcfm.com\/api\/v1\/image\/108317499-1780677508664-gettyimages-2279271814-US_STOCKS.jpeg?v=1780677967&w=1920&h=1080\" \/><meta property=\"og:image\" content=\"https:\/\/image.cnbcfm.com\/api\/v1\/image\/108317499-1780677508664-gettyimages-2279271814-US_STOCKS.jpeg?v=1780677967&w=1920&h=1080\" \/>\n<meta name=\"author\" content=\"Admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/image.cnbcfm.com\/api\/v1\/image\/108317499-1780677508664-gettyimages-2279271814-US_STOCKS.jpeg?v=1780677967&w=1920&h=1080\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ventil.rs\/blog\/health\/novo-nordisk-shares-dive-after-heart-medicine-fails-trial-dealing-another-blow-to-its-pipeline\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ventil.rs\/blog\/health\/novo-nordisk-shares-dive-after-heart-medicine-fails-trial-dealing-another-blow-to-its-pipeline\/\"},\"author\":{\"name\":\"Admin\",\"@id\":\"https:\/\/ventil.rs\/blog\/#\/schema\/person\/8b364f5cc7fbc8705a888e63db8c026a\"},\"headline\":\"Novo Nordisk shares dive after heart medicine fails trial, dealing another blow to its pipeline\",\"datePublished\":\"2026-07-31T13:33:00+00:00\",\"dateModified\":\"2026-07-31T13:33:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ventil.rs\/blog\/health\/novo-nordisk-shares-dive-after-heart-medicine-fails-trial-dealing-another-blow-to-its-pipeline\/\"},\"wordCount\":582,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/ventil.rs\/blog\/#organization\"},\"keywords\":[\"Biotech and Pharmaceuticals\",\"Breaking News: Business\",\"Breaking News: Markets\",\"Business\",\"business news\",\"Eli Lilly and Co\",\"Health care industry\",\"medication\",\"Novo Nordisk A\/S\",\"Pharmaceuticals\",\"United States\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ventil.rs\/blog\/health\/novo-nordisk-shares-dive-after-heart-medicine-fails-trial-dealing-another-blow-to-its-pipeline\/#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\/\/ventil.rs\/blog\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ventil.rs\/blog\/health\/novo-nordisk-shares-dive-after-heart-medicine-fails-trial-dealing-another-blow-to-its-pipeline\/\",\"url\":\"https:\/\/ventil.rs\/blog\/health\/novo-nordisk-shares-dive-after-heart-medicine-fails-trial-dealing-another-blow-to-its-pipeline\/\",\"name\":\"Novo Nordisk shares dive after heart medicine fails trial, dealing another blow to its pipeline - Breaking News\",\"isPartOf\":{\"@id\":\"https:\/\/ventil.rs\/blog\/#website\"},\"datePublished\":\"2026-07-31T13:33:00+00:00\",\"dateModified\":\"2026-07-31T13:33:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/ventil.rs\/blog\/health\/novo-nordisk-shares-dive-after-heart-medicine-fails-trial-dealing-another-blow-to-its-pipeline\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ventil.rs\/blog\/health\/novo-nordisk-shares-dive-after-heart-medicine-fails-trial-dealing-another-blow-to-its-pipeline\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ventil.rs\/blog\/health\/novo-nordisk-shares-dive-after-heart-medicine-fails-trial-dealing-another-blow-to-its-pipeline\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ventil.rs\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk shares dive after heart medicine fails trial, dealing another blow to its pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ventil.rs\/blog\/#website\",\"url\":\"https:\/\/ventil.rs\/blog\/\",\"name\":\"Breaking News\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/ventil.rs\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ventil.rs\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ventil.rs\/blog\/#organization\",\"name\":\"Breaking News\",\"url\":\"https:\/\/ventil.rs\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ventil.rs\/blog\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ventil.rs\/blog\/wp-content\/uploads\/2023\/07\/ventilshop-2362x591-1.png\",\"contentUrl\":\"https:\/\/ventil.rs\/blog\/wp-content\/uploads\/2023\/07\/ventilshop-2362x591-1.png\",\"width\":1445,\"height\":591,\"caption\":\"Breaking News\"},\"image\":{\"@id\":\"https:\/\/ventil.rs\/blog\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ventil.rs\/blog\/#\/schema\/person\/8b364f5cc7fbc8705a888e63db8c026a\",\"name\":\"Admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ventil.rs\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e3dd0b52c93ce674a00a0dbe8383290fdc661c12a7e48e5953f790da3887973d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e3dd0b52c93ce674a00a0dbe8383290fdc661c12a7e48e5953f790da3887973d?s=96&d=mm&r=g\",\"caption\":\"Admin\"},\"sameAs\":[\"https:\/\/ventil.rs\/blog\"],\"url\":\"https:\/\/ventil.rs\/blog\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk shares dive after heart medicine fails trial, dealing another blow to its pipeline - Breaking News","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ventil.rs\/blog\/health\/novo-nordisk-shares-dive-after-heart-medicine-fails-trial-dealing-another-blow-to-its-pipeline\/","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk shares dive after heart medicine fails trial, dealing another blow to its pipeline","og_description":"Shares of Novo Nordisk fell as much as 10% on Friday after the drugmaker said a late-stage heart drug trial failed to reduce major adverse cardiovascular events, or MACE, compared to a placebo. While the experimental medicine, ziltivekimab, did show some biological effect, it didn&#8217;t translate into a statistically meaningful reduction in MACE, defined as...Read More &ldquo;Novo Nordisk shares dive after heart medicine fails trial, dealing another blow to its pipeline&rdquo; &raquo;","og_url":"https:\/\/ventil.rs\/blog\/health\/novo-nordisk-shares-dive-after-heart-medicine-fails-trial-dealing-another-blow-to-its-pipeline\/","og_site_name":"Breaking News","article_published_time":"2026-07-31T13:33:00+00:00","og_image":[{"url":"https:\/\/image.cnbcfm.com\/api\/v1\/image\/108317499-1780677508664-gettyimages-2279271814-US_STOCKS.jpeg?v=1780677967&w=1920&h=1080"},{"url":"https:\/\/image.cnbcfm.com\/api\/v1\/image\/108317499-1780677508664-gettyimages-2279271814-US_STOCKS.jpeg?v=1780677967&w=1920&h=1080"}],"author":"Admin","twitter_card":"summary_large_image","twitter_image":"https:\/\/image.cnbcfm.com\/api\/v1\/image\/108317499-1780677508664-gettyimages-2279271814-US_STOCKS.jpeg?v=1780677967&w=1920&h=1080","twitter_misc":{"Written by":"Admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ventil.rs\/blog\/health\/novo-nordisk-shares-dive-after-heart-medicine-fails-trial-dealing-another-blow-to-its-pipeline\/#article","isPartOf":{"@id":"https:\/\/ventil.rs\/blog\/health\/novo-nordisk-shares-dive-after-heart-medicine-fails-trial-dealing-another-blow-to-its-pipeline\/"},"author":{"name":"Admin","@id":"https:\/\/ventil.rs\/blog\/#\/schema\/person\/8b364f5cc7fbc8705a888e63db8c026a"},"headline":"Novo Nordisk shares dive after heart medicine fails trial, dealing another blow to its pipeline","datePublished":"2026-07-31T13:33:00+00:00","dateModified":"2026-07-31T13:33:00+00:00","mainEntityOfPage":{"@id":"https:\/\/ventil.rs\/blog\/health\/novo-nordisk-shares-dive-after-heart-medicine-fails-trial-dealing-another-blow-to-its-pipeline\/"},"wordCount":582,"commentCount":0,"publisher":{"@id":"https:\/\/ventil.rs\/blog\/#organization"},"keywords":["Biotech and Pharmaceuticals","Breaking News: Business","Breaking News: Markets","Business","business news","Eli Lilly and Co","Health care industry","medication","Novo Nordisk A\/S","Pharmaceuticals","United States"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ventil.rs\/blog\/health\/novo-nordisk-shares-dive-after-heart-medicine-fails-trial-dealing-another-blow-to-its-pipeline\/#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/ventil.rs\/blog\/#organization"}},{"@type":"WebPage","@id":"https:\/\/ventil.rs\/blog\/health\/novo-nordisk-shares-dive-after-heart-medicine-fails-trial-dealing-another-blow-to-its-pipeline\/","url":"https:\/\/ventil.rs\/blog\/health\/novo-nordisk-shares-dive-after-heart-medicine-fails-trial-dealing-another-blow-to-its-pipeline\/","name":"Novo Nordisk shares dive after heart medicine fails trial, dealing another blow to its pipeline - Breaking News","isPartOf":{"@id":"https:\/\/ventil.rs\/blog\/#website"},"datePublished":"2026-07-31T13:33:00+00:00","dateModified":"2026-07-31T13:33:00+00:00","breadcrumb":{"@id":"https:\/\/ventil.rs\/blog\/health\/novo-nordisk-shares-dive-after-heart-medicine-fails-trial-dealing-another-blow-to-its-pipeline\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ventil.rs\/blog\/health\/novo-nordisk-shares-dive-after-heart-medicine-fails-trial-dealing-another-blow-to-its-pipeline\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ventil.rs\/blog\/health\/novo-nordisk-shares-dive-after-heart-medicine-fails-trial-dealing-another-blow-to-its-pipeline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ventil.rs\/blog\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk shares dive after heart medicine fails trial, dealing another blow to its pipeline"}]},{"@type":"WebSite","@id":"https:\/\/ventil.rs\/blog\/#website","url":"https:\/\/ventil.rs\/blog\/","name":"Breaking News","description":"","publisher":{"@id":"https:\/\/ventil.rs\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ventil.rs\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ventil.rs\/blog\/#organization","name":"Breaking News","url":"https:\/\/ventil.rs\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ventil.rs\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/ventil.rs\/blog\/wp-content\/uploads\/2023\/07\/ventilshop-2362x591-1.png","contentUrl":"https:\/\/ventil.rs\/blog\/wp-content\/uploads\/2023\/07\/ventilshop-2362x591-1.png","width":1445,"height":591,"caption":"Breaking News"},"image":{"@id":"https:\/\/ventil.rs\/blog\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ventil.rs\/blog\/#\/schema\/person\/8b364f5cc7fbc8705a888e63db8c026a","name":"Admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ventil.rs\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/e3dd0b52c93ce674a00a0dbe8383290fdc661c12a7e48e5953f790da3887973d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e3dd0b52c93ce674a00a0dbe8383290fdc661c12a7e48e5953f790da3887973d?s=96&d=mm&r=g","caption":"Admin"},"sameAs":["https:\/\/ventil.rs\/blog"],"url":"https:\/\/ventil.rs\/blog\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/ventil.rs\/blog\/wp-json\/wp\/v2\/posts\/5788","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ventil.rs\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ventil.rs\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ventil.rs\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ventil.rs\/blog\/wp-json\/wp\/v2\/comments?post=5788"}],"version-history":[{"count":0,"href":"https:\/\/ventil.rs\/blog\/wp-json\/wp\/v2\/posts\/5788\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ventil.rs\/blog\/wp-json\/wp\/v2\/media\/5789"}],"wp:attachment":[{"href":"https:\/\/ventil.rs\/blog\/wp-json\/wp\/v2\/media?parent=5788"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ventil.rs\/blog\/wp-json\/wp\/v2\/categories?post=5788"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ventil.rs\/blog\/wp-json\/wp\/v2\/tags?post=5788"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}